Prevention of Cardiac Dysfunction During Breast Cancer Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions
Breast Cancer FemaleHeart Failure
Interventions
DRUG

Sacubitril/valsartan

Target dose 97/103 mg b.i.d .

Trial Locations (4)

1478

Akershus University Hospital, Lørenskog

Unknown

Stavanger University Hospital, Stavanger

University of North Norway, Tromsø

St Olavs Hospital, Trondheim

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University Hospital, Akershus

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Klinbeforsk

OTHER

collaborator

Norwegian Cancer Society

OTHER

collaborator

Novartis

INDUSTRY

lead

Torbjorn Omland

OTHER